SCHEDULE: Roivant Boosts Immunovant Stake to 55.9% in $350M Offering

Roivant Sciences Ltd. increased its beneficial ownership in Immunovant, Inc. to 55.9% by acquiring 16.67 million shares in a recent public offering.

Summary

• Roivant Sciences Ltd. (the "Reporting Person") filed Amendment No. 10 to its Schedule 13D, updating its beneficial ownership in Immunovant, Inc. (the "Issuer").
• Roivant acquired an additional 16,666,666 shares of Immunovant Common Stock in an underwritten public offering that closed on December 12, 2025.
• The price per share in the offering was $21.00, indicating a total investment of approximately $350 million by Roivant in this transaction.
• Following this acquisition, Roivant directly beneficially owns 113,327,007 shares, representing 55.9% of Immunovant's Common Stock.
• This percentage is calculated based on 202,678,277 shares of Common Stock issued and outstanding as of December 12, 2025, which includes shares from the offering and preferred share conversions.
• Roivant's stated purpose for the purchase was to provide further capital to Immunovant for the advancement of its development pipeline, working capital, and other general corporate purposes, as well as to increase its ownership interest.

Sentiment

Score: 8

Explanation: The sentiment is positive due to a major shareholder significantly increasing its stake and providing substantial capital, indicating strong confidence and support for the company's future endeavors and pipeline development.

Positives

• Roivant Sciences, as the largest shareholder, demonstrated strong confidence in Immunovant by significantly increasing its ownership stake.
• The capital infusion from Roivant's purchase provides Immunovant with additional funds for its development pipeline, working capital, and general corporate purposes.
• Roivant explicitly stated its potential to provide additional financing to Immunovant in the future, signaling ongoing support.

Future Outlook

Roivant intends to continue supporting Immunovant's strategic objectives, including the advancement of its development pipeline. As the largest shareholder, Roivant may provide additional financing to Immunovant from time to time in the form of equity or debt securities or loans, potentially in connection with business development transactions or financing commitments.

Management Comments

• Roivant purchased shares to provide further capital to the Issuer for the advancement of the Issuer's development pipeline, working capital and other general corporate purposes.
• Roivant purchased shares to increase its ownership interest in the Issuer following the Offering.
• As the Issuer's largest shareholder, Roivant may provide additional financing to the Issuer from time to time in the form of an investment in equity or debt securities of the Issuer or loans.

Industry Context

This filing reflects a significant capital injection into a biotechnology company, common in the industry where extensive funding is required for research, development, and clinical trials. The continued strong backing from a major shareholder like Roivant indicates confidence in Immunovant's pipeline and strategic direction, which can be a positive signal in the often capital-intensive biotech sector.

Related Party Transactions

• Roivant Sciences Ltd., as a significant shareholder, acquired 16,666,666 shares of Common Stock in an underwritten public offering from Immunovant, Inc. at $21.00 per share.

Stakeholder Impact

• Shareholders: The offering likely caused some dilution for existing shareholders, but Roivant's increased stake and continued support could be seen as a positive long-term signal.
• Immunovant: Receives significant capital to fund its development pipeline and general corporate purposes, strengthening its financial position.
• Employees: Enhanced financial stability may support ongoing research and development efforts, potentially securing jobs and future growth opportunities.

Next Steps

• Immunovant will utilize the capital raised for the advancement of its development pipeline, working capital, and other general corporate purposes.
• Roivant may provide additional financing to Immunovant in the future, potentially through equity, debt, or loans.

Key Dates

Keywords

Immunovant, Roivant Sciences, Schedule 13D, equity investment, public offering, beneficial ownership, biotechnology, pharmaceuticals, capital raise